Atara biotherapeutics to participate in a panel discussion at the citi 16th annual biopharma virtual conference

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that pascal touchon, president and chief executive officer, will participate in a panel discussion titled, “autologous, allogeneic car-t, car-nk & more - exploring the state of play in cell therapy,” at the citi 16th
ATRA Ratings Summary
ATRA Quant Ranking